PeptiDream (4587) investor relations material

Executive summary

• Achieved strong clinical pipeline expansion with six new programs entering clinical development in H1 2026, reaching 19 active clinical programs and meeting full-year guidance early.

• Transitioned to a global discovery and development company, focusing on expanding the clinical pipeline, asset creation, and financial discipline.

• Maintained disciplined cost control and robust cash position, supporting continued R&D and infrastructure investments.

• Radiopharma segment delivered solid commercial growth, with PET product revenue up 30% year-on-year and total segment revenue of ¥8,025 million.

• Strengthened leadership with new executive appointments and enhanced sustainability initiatives.

Financial highlights

• H1 2026 revenue was ¥9,226.9 million, up ¥683.2 million or 8% year-over-year.

• Operating loss narrowed to ¥2,463.9 million, and profit attributable to owners improved to ¥1,999.4 million loss.

• EBITDA loss improved to ¥1,409 million, and EPS improved to ¥(15.51) from ¥(16.40) YoY.

• PET product revenue grew 30% year-on-year, led by Amyvid and FDG.

• Drug Discovery and Development business revenue rose to ¥1,201.1 million (+58% YoY).

Outlook and guidance

• FY2026 revenue guidance reaffirmed at ¥32 billion, with operating income forecast at ¥4.6 billion and net profit at ¥3 billion.

• Confident in achieving ¥15 billion revenue for drug discovery/development and ¥17 billion for Radiopharma.

• Additional upside possible from new partnerships and "plus alpha" strategic transactions not included in base guidance.

• Cash position expected to strengthen further with new deals in FY26 and FY27.